BMET-18 ASSESSING CENTRAL NERVOUS SYSTEM (CNS) RESPONSE TO ALECTINIB IN TWO PHASE II STUDIES OF PRE-TREATED ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): RECIST VERSUS RANO CRITERIA

Gelijkaardige items

• Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non–Small-Cell Lung Cancer
  door: Gadgeel, Shirish M., et al.
  Gepubliceerd in: (2016)
• Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
  door: Gadgeel, Shirish, et al.
  Gepubliceerd in: (2018)
• Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer
  door: Shaw, Alice T., et al.
  Gepubliceerd in: (2015)
• BMET-35 CERITINIB IN ALK+ NSCLC METASTATIC TO BRAIN AND/OR LEPTOMENINGES: THE ASCEND-7 STUDY
  door: Wen, Patrick Yung, et al.
  Gepubliceerd in: (2015)
• Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer
  door: Ou, Sai-Hong Ignatius, et al.
  Gepubliceerd in: (2018)